Strengthening antimicrobial resistance governance in Europe: a coordinated one health approach

Antimicrobial resistance (AMR) causes over 35,000 deaths annually in the EU/EEA and is projected to result in 1.91 million global deaths each year by 2050. The second Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections (EU-JAMRAI-2), uniting 128 partners from 30 countries, represents a coordinated EU/EEA effort to curb AMR through a One Health approach. Although nearly all EU/EEA countries have an AMR National Action Plan, our initial assessment revealed that implementation remains constrained by limited resources, weak intersectoral coordination and fragmented leadership. EU-JAMRAI-2 addresses these challenges by promoting harmonized surveillance, strengthening infection prevention and control, applying behaviorally tailored stewardship interventions, ensuring sustainable access to essential antibiotics, and raising awareness among priority target audiences. By analyzing policy gaps and operational barriers, this paper underscores the need for stronger accountability and political commitment to translate strategies into sustainable action. Strengthening AMR governance through a unified European approach is essential to achieve effective, lasting progress against this silent pandemic.

Institutions

Publication Details

Journal
The Lancet Regional Health - Europe
Published
2025-11-19
DOI
https://doi.org/10.1016/j.lanepe.2025.101540
Citations
2
Primary Topic
Antibiotic Use and Resistance
Type
article
Field-Weighted Citation Impact
2.52
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Strengthening antimicrobial resistance governance in Europe: a coordinated one health approach

2 citations
The Lancet Regional Health - Europe
Antibiotic Use and Resistance
2.52
article

Strengthening antimicrobial resistance governance in Europe: a coordinated one health approach

article en
2 citations

Abstract

Antimicrobial resistance (AMR) causes over 35,000 deaths annually in the EU/EEA and is projected to result in 1.91 million global deaths each year by 2050. The second Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections (EU-JAMRAI-2), uniting 128 partners from 30 countries, represents a coordinated EU/EEA effort to curb AMR through a One Health approach. Although nearly all EU/EEA countries have an AMR National Action Plan, our initial assessment revealed that implementation remains constrained by limited resources, weak intersectoral coordination and fragmented leadership. EU-JAMRAI-2 addresses these challenges by promoting harmonized surveillance, strengthening infection prevention and control, applying behaviorally tailored stewardship interventions, ensuring sustainable access to essential antibiotics, and raising awareness among priority target audiences. By analyzing policy gaps and operational barriers, this paper underscores the need for stronger accountability and political commitment to translate strategies into sustainable action. Strengthening AMR governance through a unified European approach is essential to achieve effective, lasting progress against this silent pandemic.

The Lancet Regional Health - EuropeVol. 61
Université Claude Bernard Lyon 1 (FR), Statens Serum Institut (DK), Public Health Agency of Sweden (SE), Ministry of Health Welfare and Sport (NL), Norwegian Institute of Public Health (NO), Inserm (FR), Université de Versailles Saint-Quentin-en-Yvelines (FR), Université Paris-Saclay (FR), Servei de Salut de les Illes Balears (ES), Departament de Salut (ES), Assistance Publique – Hôpitaux de Paris (FR), Institut Català d'Oncologia (ES), Ministère des Solidarités et de la Santé (FR), Centre Hospitalier Universitaire de Limoges (FR), Hôpital Raymond-Poincaré (FR), Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail (FR), Bioef - Fundación Vasca de Innovación e Investigación Sanitarias (ES), National Public Health Organization (GR), Institut Català de la Salut (ES), Université de Limoges (FR), Pharmaceuticals and Medical Devices Agency (JP)
Partnerships for the goals
Openalex Percentile: Top 8%
Antibiotic Use and Resistance
2.52
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.